Archives

PolyAI opens its Agentic Dialog Platform, making the tech behind complex conversations for hundreds of enterprises available to every builder

B Powered by a model purpose-built for dialog & proven on a billion conversations, PolyAI’s platform delivers agents in minutes for complex deployments at any… Login to continue reading Login…

Read MorePolyAI opens its Agentic Dialog Platform, making the tech behind complex conversations for hundreds of enterprises available to every builder

Flavored vapes led to a major shake-up at the FDA – 3 health policy analysts explain the science behind the controversial products

C The resignation of Marty Makary, commissioner of the U.S. Food and Drug Administration, on May 12, 2026, brought to the forefront a heated controversy… Login to continue reading Login…

Read MoreFlavored vapes led to a major shake-up at the FDA – 3 health policy analysts explain the science behind the controversial products

FDA Approves IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi), First Biosimilars to Simponi® (golimumab) and Simponi Aria® (golimumab); Accord BioPharma to Lead U.S. Commercialization

B FDA approval of IMMGOLIS and IMMGOLIS INTRI breaks new ground in patient access, marking the first biosimilar option to golimumab biologic therapy in the… Login to continue reading Login…

Read MoreFDA Approves IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi), First Biosimilars to Simponi® (golimumab) and Simponi Aria® (golimumab); Accord BioPharma to Lead U.S. Commercialization